1型糖尿病中口服碳水化合物管理即将发生的非严重低血糖:REVERSIBLE试验
REVERSIBLE试验为开放标签交叉研究,29例1型糖尿病患者在空腹状态下经皮下胰岛素诱导血糖下降后,分别在血糖<70、≤80或≤90 mg/dL时口服16 g碳水化合物。结果显示在≤90 mg/dL时干预可减少低血糖发生率和持续时间,且未出现显著反弹高血糖。
要点
- 在血糖≤90 mg/dL时口服16 g碳水化合物,仅34%参与者发生低血糖,低于<70 mg/dL组的100%。
- ≤90 mg/dL组低血糖持续7.1±11.8分钟,短于<70 mg/dL组的26.0±12.6分钟。
- ≤90 mg/dL组31%参与者需多次治疗维持血糖正常,低于<70 mg/dL组的69%。
核心结论
- 对于部分即将发生的非严重低血糖事件,1型糖尿病患者在较高血糖水平时摄入碳水化合物可能获益。
研究设计与样本
- 开放标签交叉研究,共纳入29例1型糖尿病患者,在空腹状态下经皮下胰岛素诱导血糖下降后,于血浆葡萄糖<70、≤80或≤90 mg/dL时口服16 g碳水化合物。
主要发现
- 从<70(对照)到≤80和≤90 mg/dL治疗组,发生低血糖的参与者比例分别为100% vs 86%(P=0.1201)vs 34%(P<0.0001)。
- 低血糖事件持续时间分别为26.0±12.6 vs 17.9±14.7(P=0.026)vs 7.1±11.8分钟(P=0.002)。
- 血浆葡萄糖最低值分别为56.57±9.91 vs 63.60±7.93(P=0.008)vs 73.51±9.37 mg/dL(P=0.002)。
- 对照组69%的参与者需要超过一次治疗才能达到或维持血糖正常(≥70 mg/dL),≤80 mg/dL组为52%,≤90 mg/dL组为31%。
- 第一小时内无显著反弹高血糖(>180 mg/dL)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend initiating treatment for nonsevere (NS) hypoglycemia with 15 g carbohydrates (CHO) at 15-min intervals when blood glucose (BG) reaches <70 mg/dL (3.9 mmol/L). Despite this recommendation, NS hypoglycemia management remains challenging for individuals living with type 1 diabetes (T1D). We aimed to assess the efficacy of 15 g CHO at higher BG levels. RESEARCH DESIGN AND METHODS: A total of 29 individuals with T1D participated in an open-label crossover study. After an inpatient subcutaneous insulin-induced decrease in BG in the fasting state, 16 g CHO was administered orally at a plasma glucose (PG) of <70 (3.9), ≤80 (4.5), or ≤90 mg/dL (5.0 mmol/L). The primary outcome was time spent in hypoglycemia (<70 mg/dL) after initial CHO intake. RESULTS: When comparing the <70 (control) with the ≤80 and ≤90 mg/dL treatment groups, 100 vs. 86 (P = 0.1201) vs. 34% (P < 0.0001) of participants reached hypoglycemia, respectively. These hypoglycemic events lasted 26.0 ± 12.6 vs. 17.9 ± 14.7 (P = 0.026) vs. 7.1 ± 11.8 min (P = 0.002), with a PG nadir of 56.57 ± 9.91 vs. 63.60 ± 7.93 (P = 0.008) vs. 73.51 ± 9.37 mg/dL (P = 0.002), respectively. In the control group, 69% of participants required more than one treatment to reach or maintain normoglycemia (≥70 mg/dL), compared with 52% in the ≤80 mg/dL group and 31% in the ≤90 mg/dL group, with no significant rebound hyperglycemia (>180 mg/dL) within the first hour. CONCLUSIONS: For some impending NS hypoglycemia episodes, individuals with TID could benefit from CHO intake at a higher BG level.
引用
- Cheng R, Taleb N, Wu Z, et al. Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial. Diabetes Care. 2024. PMID: 38194601. doi:10.2337/dc23-1328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。